osteoporosis in dialysis patients
Conditions
Interventions
adminstrate minedonorate 50mg monthly for 52 weeks
Sponsors
Oita university facility of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients receving hemodialysis including these criteria 1)osteoprotic patients 2)Age-lower limit:18 years old, age-higher limit:85 years old 3)Patients with informed of consent 4)i-PTH:60-240
Exclusion criteria
Exclusion criteria: 1)Patients who have obstacles which delays esophagus passage of stricture of the esophagus or achalasia 2)Patients who have raised the upper part of the body for 30 minutes or it cannot be standing 3)hypersensitivity for bisphosphonate 4)The patient with hypocalcemia 5)Patients in or expecting pregnancy 6)Patients who diagnosed malignancy 7)Patients receiving specific treatments that affect bone and mineral metabolism such as recombinant human PTH, and Eldecalcitol 8)Patients who took SERM within a month before this trial 9)Patients who took bisphophonate within 6 month before this trial 10)Patients who are inappropriate for this study by physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of bone mineral density and safty of minodoronate | — |
Countries
Japan
Contacts
Public ContactTakeshi Nakata
Oita university facility of medicine internal medicine 2
Outcome results
None listed